INCLUSION CRITERIA:  In order to be eligible to participate in this study, an individual must meet all of the following criteria:  Meets one of the following:  Has documentation of PID confirmed by genetic evaluation demonstrating a deleterious variant in the gene (or genes) known to be associated with immune deficiency (confirmed PID); or Has documented variant of undetermined significance in a gene (or genes) that is predicted to be deleterious in immune function by the investigators AND a clinical history of infections which are more frequent, more chronic, or more severe than normal (suspected PID); or Has physician-diagnosed psoriasis; or Has physician-diagnosed AD; or Does not have clinically apparent evidence of any monogenic or digenic immune defect, AD, or psoriasis (healthy volunteers). Aged 18 to 75 years. Willing to allow storage of blood, biopsy tissue, and bacterial and fungal cultures for future research. Able to provide informed consent.  EXCLUSION CRITERIA:  An individual who meets any of the following criteria will be excluded from participation in this study:  Current or prior (within 3 months) anticoagulant or anti-platelet therapy (other than aspirin or non-steroidal anti-inflammatory drugs). Current or prior (within 3 months) use of immunomodulatory drugs (eg, chemotherapy, steroids), except if approved by the principal investigator. History of keloid formation. Pregnancy, lactating, or breastfeeding. Any condition that, in the opinion of the investigator, contraindicates participation in the study.